Please assess the completion status of the following clinical trial:

Trial Title: Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. History of remote myocardial infarction~2. Left ventricular ejection fraction ≥ 30 to ≤ 50 % as estimated by cardiac MRI, 3D-echocardiography or via ventriculography within 30 days before enrollment~3. Documentation of sustained ventricular tachycardia (VT) by any kind of Electrocardiography (ECG) including 12 lead ECG, holter ECG, rhythm strip, event monitoring, event recorder or pacemaker within 30 days before enrollment~4. Implantable cardioverter-defibrillator (ICD) indication for secondary prevention~5. Patients who are planned to be implanted with BIOTRONIK ICDs (single, dual, triple chamber or DX device)~6. Patient has provided written informed consent~7. Patient accepts activation of Home Monitoring®~Exclusion Criteria:~1. Age \< 18 years or \> 80 years~2. Known arterial or venous thrombosis~3. Class IV New York Heart Association (NYHA) heart failure~4. Valvular heart disease or mechanical heart valve precluding access to the left ventricle~5. Acute myocardial reinfarction or acute coronary syndrome~6. Cardiac surgery involving cardiotomy within the past 2 months~7. Patients requiring chronic renal dialysis~8. Thrombocytopenia or coagulopathy~9. Incessant VT or electrical storm~10. Bundle branch reentry tachycardia as the presenting VT~11. Pre-existing implantable cardioverter-defibrillator (ICD)~12. Pregnancy or breast feeding women~13. Acute illness or active systemic infection~14. Other disease process likely to limit survival to less than 12 months~15. Significant medical problem that in the opinion of the principal investigator would preclude enrollment in the study~16. Unwillingness to participate or lack of availability for follow-up~17. Participation in another interventional clinical investigation during the course of the study, i.e. the participation in a non-interventional clinical investigation is allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (TG1) (Type: EXPERIMENTAL): Prophylactic VT ablation prior to ICD implantation
- Treatment Group 2 (TG2) (Type: OTHER): ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter

Based on this trial design, predict the completion outcome and termination type (if applicable).